Workflow
专利
icon
Search documents
中芯国际申请测试装置及测试方法专利,提高对 IGBT 晶圆的测试效率
Sou Hu Cai Jing· 2025-05-14 03:54
Core Insights - Semiconductor manufacturing companies in China, specifically SMIC's subsidiaries, have applied for a patent related to a testing device and method for IGBT wafers, which aims to enhance testing efficiency and accuracy [1][3] Company Overview - SMIC International Integrated Circuit Manufacturing (Tianjin) Co., Ltd. was established in 2003, located in Tianjin, with a registered capital of 129 million USD. The company has participated in 104 bidding projects and holds 385 patents [2] - SMIC North Integrated Circuit Manufacturing (Beijing) Co., Ltd. was founded in 2013, based in Beijing, with a registered capital of 480 million USD. It has engaged in 45 bidding projects and possesses 133 patents [2] - SMIC International Integrated Circuit Manufacturing (Shanghai) Co., Ltd. was established in 2000, located in Shanghai, with a registered capital of 244 million USD. The company has invested in 4 enterprises, participated in 127 bidding projects, and holds 5000 patents [2]
深圳市郑中设计股份有限公司关于累计诉讼、仲裁情况的公告
Group 1: Litigation and Arbitration Summary - As of the announcement date, the company has received a total of 171.27 million yuan in new litigation and arbitration cases over the past twelve months, which accounts for more than 10% of the company's most recent audited net assets [1][4] - The company is involved in litigation and arbitration as both a plaintiff/applicant (136.57 million yuan) and a defendant/respondent (34.70 million yuan) [1][4] - There are no significant undisclosed litigation or arbitration matters that exceed 10% of the company's most recent audited net assets or 10 million yuan in absolute amount [3] Group 2: Impact on Financials - The impact of the ongoing litigation and arbitration on the company's financial status, current profits, and future profits remains uncertain due to the unpredictable nature of the litigation outcomes [4] - The company will handle accounting in accordance with accounting standards and will monitor the progress of the cases closely [4] Group 3: Patent Acquisition - The company's wholly-owned subsidiary has recently obtained a utility model patent, which is expected to enhance the company's technological research and development capabilities [7] - The acquisition of the patent is not expected to have a significant impact on the company's operations but is likely to positively influence market expansion and brand influence [7]
梯瓦计划裁员约8%,跨国药企如何在风暴中重塑增长?
Group 1: Company Strategy and Financial Performance - Teva aims to transform into a biopharmaceutical company, targeting approximately $700 million in net savings by 2027 while offsetting the profit loss from the generic version of Revlimid and achieving a 30% operating profit margin [2] - The company reported a revenue of $3.9 billion in Q1 2025, a 5% increase year-over-year, with innovative products contributing significantly to this growth [7][8] - Teva's U.S. revenue reached $1.91 billion in Q1 2025, a 10.72% increase, with a profit of $532 million, reflecting a 52% year-over-year growth [8] Group 2: Cost-Cutting Measures - Teva plans to reduce general and administrative expenses by 100 basis points through the use of business centers, AI, and digital tools [2] - The company intends to lay off approximately 8% of its workforce, affecting around 2,400 employees, marking the largest reduction in three years [9] - Teva is also looking to consolidate suppliers to cut spending by about 10% [2] Group 3: Market Challenges and Industry Trends - The global pharmaceutical industry is experiencing a downturn, prompting many companies, including Teva, to implement cost control measures to maintain operations and R&D investments [5][11] - The industry faces challenges such as patent expirations and increased competition from generics, leading companies to adjust their R&D pipelines and focus on higher return products [13][14] - Teva's strategic shift is part of a broader trend among multinational pharmaceutical companies to optimize operations and adapt to a complex market environment [6][11]
小米汽车前保险杠风道专利获授权
news flash· 2025-05-13 06:44
金十数据5月13日讯,天眼查财产线索信息显示,近日,小米汽车科技有限公司申请的"前保险杠风道和 车辆"专利获授权。摘要显示,本公开所述前保险杠风道包括风道本体和活动板,所述风道本体围成有 风道;所述活动板的至少一部分设于所述风道本体内,所述活动板与所述风道本体转动连接,以在关闭 所述风道的第一位置和开启所述风道的第二位置之间切换。本公开的前保险杠风道,通过转动活动板可 以实现对车辆前轴升力的调节,改善车辆操控性能。 小米汽车前保险杠风道专利获授权 ...
中天科技申请气吹光缆及其生产工艺专利,提升光缆在气吹施工中的减摩效果及耐磨性能
Jin Rong Jie· 2025-05-13 04:45
天眼查资料显示,江苏中天科技股份有限公司,成立于1996年,位于南通市,是一家以从事电气机械和 器材制造业为主的企业。企业注册资本341294.9652万人民币。通过天眼查大数据分析,江苏中天科技 股份有限公司共对外投资了56家企业,参与招投标项目5000次,财产线索方面有商标信息70条,专利信 息1832条,此外企业还拥有行政许可6881个。 专利摘要显示,一种气吹光缆及其生产工艺,包括有缆芯和包覆在所述缆芯外的外护套,所述缆芯包括 有若干光纤以及将若干所述光纤在轴向间断粘接的粘接部,在所述外护套成型后,再在所述外护套上设 置有凸出件,所述凸出件呈螺旋状环绕在所述外护套的外表面,所述凸出件沿气吹光缆的径向朝外侧延 伸且凸出于外护套。通过将凸出件与外护套分离成型,避免了一体挤塑时凸出件受热冷却不均而造成的 形变;同时,凸出件可根据不同施工环境灵活选材,有助于提升光缆在气吹施工中的减摩效果及耐磨性 能;根据不同施工环境,实现光缆凸出件的稳定性与材料的灵活选择,以有效降低冷却成型过程中凸出 件易变形的问题,并可根据需求选取不同材料以满足光缆的综合性能需求。 金融界2025年5月13日消息,国家知识产权局信息显示, ...
江苏启动“双季”科技成果转化活动首推“先使用后付费”专利许可模式
Xin Hua Ri Bao· 2025-05-12 23:16
"拍卖季"聚焦科技成果供给侧,面向全省高校院所、科研机构广泛征集优质专利及技术成果,采 用"网络竞拍+协议成交"模式,推动科研成果以市场化方式快速落地企业。"挑战季"则立足企业需求 端,围绕生物医药、先进材料、信息通信、人工智能、智能制造等七大重点产业领域,公开征集企业在 技术改造、产品升级中的"卡脖子"难题,以及定制化解决方案。各领域"热门需求榜单"不仅在省科技资 源统筹服务云平台发布,还将根据产业领域推送给高校院所、计量技术机构等。对于在"挑战季"中促成 合作的项目,地方科技主管部门建立项目库,常态化开展跟踪问效服务,确保项目落地;对于未获得有 效解决方案的需求项目,省技术产权交易市场及各分中心继续做好服务,积极促进供需对接。 除引入"先使用后付费"专利许可模式外,今年活动还有些变化。比如,为进一步加快计量技术创新 和产业发展,主办单位中新增省市场监督管理局;省科技资源统筹服务中心(省技术产权交易市场)、 省高校科技发展中心,将按照"优势学科+优势产业"模式,促成高新区和高校协同,推动高校科技成果 落地转化。 2025年江苏省"成果(专利)拍卖季"与"J-TOP创新挑战季"近日拉开帷幕。作为全省科技成果转 ...
危中有机最惠国定价(MFN)解读 & 国内创新药出海机遇
2025-05-12 15:16
危中有机最惠国定价(MFN)解读 & 国内创新药出海机 遇 20250512 摘要 • 《通货膨胀削减法案》通过医保谈判降低药品价格,首批 10 个药品降幅 达 38%-79%,但实际出厂价仅降 22%,渠道费用占据大部分降幅,对药 企压力相对可控,销售额 100 亿美元的创新药受影响约为 5.5 亿美元。 • 专利悬崖和美国药品定价压力为中国创新药企带来出海机遇,通过技术创 新和国际合作进入全球市场,缓解国内竞争压力,实现利润增长,并规避 美国复杂支付体系的风险。 • 中国创新药 license in 交易持续增长,2023 年占比达 32%,表明其质量 和海外商业化确定性较高,主要得益于人才、临床资源和 me-too 创新模 式,以及专利悬崖和定价压力下的成本控制需求。 • 专利悬崖问题严峻,预计到 2028 年将有 1,000 亿美元专利药收入面临仿 制药竞争,导致销售额下降 320 亿美元,迫使跨国药企通过外部合作和收 购补充管线。 • 大型跨国药企通过外部合作补充管线,占比高达 65%,并拥有大量现金储 备,截至 2024 年 6 月 30 日可用于收购金额达 4,800 亿美元,积极应对 市场压力 ...
康泰医学订单减少净利4连降陷亏损 胡坤独揽2.3亿分红拟再套现1.68亿
Chang Jiang Shang Bao· 2025-05-12 00:34
Core Viewpoint - The stock price of Kangtai Medical has plummeted significantly since its IPO, leading to a drastic reduction in market capitalization and shareholder value, prompting the major shareholder to initiate a share reduction plan [1][2][8]. Group 1: Stock Performance and Market Capitalization - Kangtai Medical's market capitalization has dropped from over 120 billion yuan to approximately 5.46 billion yuan, representing a decline of 95.58%, which equates to a loss of about 117 billion yuan [2][7]. - The stock price reached a peak of 307.03 yuan per share at the time of listing but has since fallen to a historical low of 13.97 yuan per share [2][7]. Group 2: Financial Performance - Since 2021, Kangtai Medical has experienced a continuous decline in net profit for four consecutive years, with a reported loss of 77.9 million yuan in 2024 [3][9]. - The company's revenue has also decreased, with 2021 revenue at 909 million yuan, down 35.15% year-on-year, and subsequent years showing further declines [10][11]. - Despite the financial downturn, the company has maintained high dividend payouts, totaling approximately 392 million yuan from 2020 to 2023, with the major shareholder receiving around 230 million yuan [4][12][13]. Group 3: Shareholder Actions - On May 8, 2024, the controlling shareholder, Hu Kun, announced plans to reduce his holdings by up to 12 million shares, which could yield approximately 168 million yuan [6][7]. - This marks Hu Kun's first instance of cashing out since the company's IPO, amidst a trend of frequent share reductions by executives and shareholders since 2021 [8]. Group 4: Product Quality and Legal Issues - In 2024, Kangtai Medical faced scrutiny over product quality, with several products failing to meet standards, resulting in a fine of 30,000 yuan [16][17]. - The company was also involved in a patent infringement lawsuit with Beijing Chao Si Electronic Technology, which was settled in December 2024 for 1 million USD [19][20][21].
海康威视取得摄像机用线缆和摄像机系统专利,实现对摄像机状态的稳定、直观显示
Jin Rong Jie· 2025-05-10 09:06
Group 1 - The company Hangzhou Hikvision Digital Technology Co., Ltd. has obtained a patent for a "cable for cameras and camera systems," with the authorization announcement number CN222839731U, applied for on April 2024 [1] - The patent describes a cable that includes a main body with two free ends, where the first free end connects to the camera and includes a network interface, power interface, and an indicator light interface, while the second free end connects to external devices and power supply [1] - The implementation of this patent allows for stable and intuitive display of the camera's status through the indicator light when connected to the power supply or external devices [1] Group 2 - Hangzhou Hikvision Digital Technology Co., Ltd. was established in 2001 and is located in Hangzhou, primarily engaged in the manufacturing of computers, communications, and other electronic devices [2] - The company has a registered capital of approximately 923.32 million RMB and has invested in 67 enterprises, participated in 5000 bidding projects, and holds 5000 patent information records [2] - Additionally, the company has 833 trademark information records and 568 administrative licenses [2]
沈阳海尔电冰箱申请冰箱专利,能够自动灵活实现搁架上下调整
Jin Rong Jie· 2025-05-10 06:00
Group 1 - The State Intellectual Property Office of China has published a patent application by Shenyang Haier Refrigerator Co., Ltd. for a new type of refrigerator, indicating innovation in the appliance sector [1] - The patent includes a mechanism for automatic height adjustment of shelves using a motor-driven pulley system, which enhances user convenience and reduces the required motor power [1] - Shenyang Haier Refrigerator Co., Ltd. was established in 2011 with a registered capital of 100 million RMB and has participated in 325 bidding projects and holds 133 patents [1] Group 2 - Haier Smart Home Co., Ltd. was founded in 1994 with a registered capital of approximately 943.81 million RMB and is primarily engaged in other manufacturing industries [2] - The company has made investments in 58 enterprises and has participated in 1,624 bidding projects, showcasing its active role in the market [2] - Haier Smart Home holds 5,000 patents and has 285 trademark registrations, indicating a strong focus on innovation and brand protection [2]